{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:03:54Z","timestamp":1787598234346,"version":"build-2736575974"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Most drugs fail during development and there is a clear and unmet need for approaches to better understand mechanistically how drugs exert both their intended and adverse effects. Gaining traction in this field is the use of disease data linking genes with pathological phenotypes and combining this with drugtarget interaction data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We introduce methodology to associate drugs with effects, both intended and adverse, using a tripartite network approach that combines drug-target and target-phenotype data, in which targets can be represented as proteins and protein domains.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We were able to detect associations for over 140,000 ChEMBL drugs and 3,800 phenotypes, represented as Human Phenotype Ontology (HPO) terms. The overlap of these results with the SIDER databases of known drug side effects was up to 10 times higher than random, depending on the target type, disease database and score threshold used. In terms of overlap with drug-phenotype pairs extracted from the literature, the performance of our methodology was up to 17.47 times greater than random. The top results include phenotype-drug associations that represent intended effects, particularly for cancers such as chronic myelogenous leukemia, which was linked with nilotinib. They also include adverse side effects, such as blurred vision being linked with tetracaine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This work represents an important advance in our understanding of how drugs cause intended and adverse side effects through their action on disease causing genes and has potential applications for drug development and repositioning.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1470931","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T07:11:32Z","timestamp":1737529892000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Better understanding the phenotypic effects of drugs through shared targets in genetic disease networks"],"prefix":"10.3389","volume":"15","author":[{"given":"Elena","family":"D\u00edaz-Santiago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelio A.","family":"Moya-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Yahyaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Orengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencio","family":"Pazos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A. G.","family":"Ranea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/J.LRR.2018.05.003","article-title":"Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase","volume":"11","author":"Alqasim","year":"2018","journal-title":"Leukemia Res. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/nmeth.2728","article-title":"Using networks to measure similarity between genes: association index selection","volume":"10","author":"Bass","year":"2013","journal-title":"Nat. Methods"},{"key":"B3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/S12032-012-0348-Z","article-title":"Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia","volume":"30","author":"Bennour","year":"2013","journal-title":"Med. Oncol. N. Lond. Engl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"D267","DOI":"10.1093\/NAR\/GKH061","article-title":"The unified Medical Language System (UMLS): integrating biomedical terminology","volume":"32","author":"Bodenreider","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"100230","DOI":"10.1016\/j.jadr.2021.100230","article-title":"Isotretinoin and neuropsychiatric side effects: continued vigilance is needed","volume":"6","author":"Bremner","year":"2021","journal-title":"J. Affect. Disord. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41431-018-0139-x","article-title":"Phenotype-loci associations in networks of patients with rare disorders: application to assist in the diagnosis of novel clinical cases","volume":"26","author":"Bueno","year":"2018","journal-title":"Eur. J. Hum. Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/SCIENCE.1158140","article-title":"Drug target identification using side-effect similarity","volume":"321","author":"Campillos","year":"2008","journal-title":"Sci. (New York, N.Y.)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1002\/CNCR.26062","article-title":"Practical management of patients with chronic myeloid leukemia","volume":"117","author":"Cervantes","year":"2011","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/17460441.2020.1767063","article-title":"An up-to-date overview of computational polypharmacology in modern drug discovery","volume":"15","author":"Chaudhari","year":"2020","journal-title":"Expert Opin. drug Discov."},{"key":"B10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17460441.2017.1280024","article-title":"Computational polypharmacology: a new paradigm for drug discovery","volume":"12","author":"Chaudhari","year":"2017","journal-title":"Expert Opin. drug Discov."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/J.JBI.2010.08.005","article-title":"Using text to build semantic networks for pharmacogenomics","volume":"43","author":"Coulet","year":"2010","journal-title":"J. Biomed. Inf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000316508","article-title":"Withdrawal of sibutramine for weight loss: where does this leave clinicians?","volume":"3","author":"Czernichow","year":"2010","journal-title":"Obes. Facts"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/BIOINFORMATICS\/BTAA937","article-title":"CATH functional families predict functional sites in proteins","volume":"37","author":"Das","year":"2021","journal-title":"Bioinforma. Oxf. Engl."},{"key":"B14","doi-asserted-by":"publisher","first-page":"W612","DOI":"10.1093\/NAR\/GKV352","article-title":"ChEMBL web services: streamlining access to drug discovery data and utilities","volume":"43","author":"Davies","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"101487","DOI":"10.1016\/j.isci.2020.101487","article-title":"Mechanism of action and target identification: a matter of timing in drug discovery","volume":"23","author":"Davis","year":"2020","journal-title":"iScience"},{"key":"B16","first-page":"137","volume-title":"The classification of protein domains","author":"Dawson","year":"2017"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/J.CLINTHERA.2008.11.014","article-title":"Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia","volume":"30","author":"DeRemer","year":"2008","journal-title":"Clin. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"635074","DOI":"10.3389\/fmolb.2021.635074","article-title":"Decoding neuromuscular disorders using phenotypic clusters obtained from Co-occurrence networks","volume":"8","author":"D\u00edaz-Santiago","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1009054","DOI":"10.1371\/journal.pgen.1009054","article-title":"Phenotype-genotype comorbidity analysis of patients with rare disorders provides insight into their pathological and molecular bases","volume":"16","author":"D\u00edaz-Santiago","year":"2020","journal-title":"PLOS Genet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/J.CMPB.2019.04.029","article-title":"An adverse drug effect mentions extraction method based on weighted online recurrent extreme learning machine","volume":"176","author":"drissiya El-allaly","year":"2019","journal-title":"Comput. methods programs Biomed."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41467-021-21843-8","article-title":"Identifying therapeutic drug targets using bidirectional effect genes","volume":"12","author":"Estrada","year":"2021","journal-title":"Nat. Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/CVM-2-5-205","article-title":"Withdrawal of cerivastatin from the world market","volume":"2","author":"Furberg","year":"2001","journal-title":"Curr. Control. Trials Cardiovasc. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/MSB.2011.26","article-title":"PREDICT: a method for inferring novel drug indications with application to personalized medicine","volume":"7","author":"Gottlieb","year":"2011","journal-title":"Mol. Syst. Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e6536","DOI":"10.1371\/JOURNAL.PONE.0006536","article-title":"Human disease-drug network based on genomic expression profiles","volume":"4","author":"Hu","year":"2009","journal-title":"PloS one"},{"key":"B25","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1471-2105-16-S13-S4","article-title":"DMAP: a connectivity map database to enable identification of novel drug repositioning candidates","volume":"16","author":"Huang","year":"2015","journal-title":"BMC Bioinforma."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1101\/2023.05.26.23290615","article-title":"Explainable drug side effect prediction via biologically informed graph neural network","author":"Huang","year":"2023"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1186\/1752-0509-7-S6-S18","article-title":"Inferring protein domains associated with drug side effects based on drug-target interaction network","volume":"7","author":"Iwata","year":"2013","journal-title":"BMC Syst. Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/S13321-020-00450-7","article-title":"A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions","volume":"12","author":"Jarada","year":"2020","journal-title":"J. cheminformatics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/BIB\/BBR028","article-title":"Mining small-molecule screens to repurpose drugs","volume":"12","author":"Joshua Swamidass","year":"2011","journal-title":"Briefings Bioinforma."},{"key":"B30","doi-asserted-by":"publisher","first-page":"106055","DOI":"10.1016\/J.PHRS.2021.106055","article-title":"Polypharmacology: the science of multi-targeting molecules","volume":"176","author":"Kabir","year":"2022","journal-title":"Pharmacol. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1000423","DOI":"10.1371\/JOURNAL.PCBI.1000423","article-title":"Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis","volume":"5","author":"Kinnings","year":"2009","journal-title":"PLoS Comput. Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"D1207","DOI":"10.1093\/NAR\/GKAA1043","article-title":"The human phenotype ontology in 2021","volume":"49","author":"K\u00f6hler","year":"2021","journal-title":"Nucleic acids Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12859-022-04590-5","article-title":"DrugShot: querying biomedical search terms to retrieve prioritized lists of small molecules","volume":"23","author":"Kropiwnicki","year":"2022","journal-title":"BMC Bioinforma."},{"key":"B34","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1471-2105-13-S17-S11","article-title":"Mapping small molecule binding data to structural domains","volume":"13","author":"Kruger","year":"2012","journal-title":"BMC Bioinforma."},{"key":"B35","doi-asserted-by":"publisher","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","article-title":"The SIDER database of drugs and side effects","volume":"44","author":"Kuhn","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/SCIENCE.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Sci. (New York, N.Y.)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/1471-2105-12-S2-S2","article-title":"Building the process-drug\u2013side effect network to discover the relationship between biological Processes and side effects","volume":"12","author":"Lee","year":"2011","journal-title":"BMC Bioinforma."},{"key":"B38","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1186\/S12859-018-2490-X","article-title":"Drug repositioning using drug-disease vectors based on an integrated network","volume":"19","author":"Lee","year":"2018","journal-title":"BMC Bioinforma."},{"key":"B39","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1186\/S12859-016-1336-7","article-title":"Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks","volume":"17","author":"Liu","year":"2016","journal-title":"BMC Bioinforma."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(05)78800-0","article-title":"What lessons can be learnt from withdrawal of mibefradil from the market?","volume":"351","author":"Li Wan Po","year":"1998","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"8846","DOI":"10.1038\/s41598-020-65658-x","article-title":"A computational drug repositioning method applied to rare diseases: adrenocortical carcinoma","volume":"10","author":"Lotfi Shahreza","year":"2020","journal-title":"Sci. Rep. 2020"},{"key":"B42","doi-asserted-by":"publisher","first-page":"100874","DOI":"10.1016\/J.TRANON.2020.100874","article-title":"KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: a single-site report","volume":"13","author":"Luo","year":"2020","journal-title":"Transl. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"D930-D940","DOI":"10.1093\/NAR\/GKY1075","article-title":"ChEMBL: towards direct deposition of bioassay data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"10102","DOI":"10.1038\/s41598-017-10012-x","article-title":"Structural and functional view of polypharmacology","volume":"7","author":"Moya-Garc\u00eda","year":"2017","journal-title":"Sci. Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1093\/bioinformatics\/btt321","article-title":"Insights into polypharmacology from drug-domain associations","volume":"29","author":"Moya-Garc\u00eda","year":"2013","journal-title":"Bioinformatics"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1128\/MCB.20.4.1179-1186.2000","article-title":"The survival function of the bcr-abl oncogene is mediated by bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and raf","volume":"20","author":"Neshat","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/S41467-019-09407-3","article-title":"Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects","volume":"10","author":"Nguyen","year":"2019","journal-title":"Nat. Commun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","article-title":"Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature","volume":"14","author":"Onakpoya","year":"2016","journal-title":"BMC Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1479-5876-10-178","article-title":"Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia","volume":"10","author":"Palomba","year":"2012","journal-title":"J. Transl. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"167568","DOI":"10.1016\/j.jmb.2022.167568","article-title":"CoMent: relationships between biomedical concepts inferred from the scientific literature","author":"Pazos","year":"2022","journal-title":"J. Mol. Biol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"349ps15","DOI":"10.1126\/SCITRANSLMED.AAF2608","article-title":"Disciplined approach to drug discovery and early development","volume":"8","author":"Plenge","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e14012","DOI":"10.7554\/ELIFE.14012","article-title":"Epidermal RAF prevents allergic skin disease","volume":"5","author":"Raguz","year":"2016","journal-title":"eLife"},{"key":"B53","first-page":"197","article-title":"Revealing the relationship between human genome regions and pathological phenotypes through network analysis","volume-title":"Lecture notes in computer science (including subseries lecture notes in artificial intelligence and lecture notes in bioinformatics)","author":"Rojano","year":"2017"},{"key":"B54","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/BIB\/BBS082","article-title":"Pharmaco-miR: linking microRNAs and drug effects","volume":"15","author":"Rukov","year":"2014","journal-title":"Briefings Bioinforma."},{"key":"B55","doi-asserted-by":"publisher","first-page":"6848","DOI":"10.1038\/s41467-021-27138-2","article-title":"Network medicine for disease module identification and drug repurposing with the NeDRex platform","volume":"12","author":"Sadegh","year":"2021","journal-title":"Nat. Commun."},{"key":"B56","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1073\/PNAS.92.12.5287","article-title":"Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2","volume":"92","author":"S\u00e1nchez-Garc\u00eda","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B57","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2174\/1574893611666160212235117","article-title":"AutoFlow, a versatile workflow engine illustrated by assembling an optimised de novo transcriptome for a non-model species, such as faba bean (Vicia faba)","volume":"11","author":"Seoane","year":"2016","journal-title":"Curr. Bioinforma."},{"key":"B58","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/J.JBI.2014.07.011","article-title":"Identifying plausible adverse drug reactions using knowledge extracted from the literature","volume":"52","author":"Shang","year":"2014","journal-title":"J. Biomed. Inf."},{"key":"B59","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/B978-0-7234-3412-2.10015-X","article-title":"Pharmacotherapy of acute orofacial pain","author":"Sharav","year":"2008","journal-title":"Orofac. Pain Headache"},{"key":"B60","doi-asserted-by":"publisher","first-page":"D704-D715","DOI":"10.1093\/nar\/gkz997","article-title":"The Monarch Initiative in 2019: an integrative data and analytic platform connecting phenotypes to genotypes across species","volume":"48","author":"Shefchek","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"D266","DOI":"10.1093\/nar\/gkaa1079","article-title":"Cath: increased structural coverage of functional space","volume":"49","author":"Sillitoe","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"D266","DOI":"10.1093\/nar\/gkaa1079","article-title":"CATH: increased structural coverage of functional space","volume":"49","author":"Sillitoe","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","article-title":"Discovery and preclinical validation of drug indications using compendia of public gene expression data","volume":"3","author":"Sirota","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/GENES10020159","article-title":"Inferring drug-protein\u2013side effect relationships from biomedical text","volume":"10","author":"Song","year":"2019","journal-title":"Genes"},{"key":"B65","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.4103\/0976-500X.120957","article-title":"Clinical and economic burden of adverse drug reactions","volume":"4","author":"Sultana","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1101\/2022.04.13.22273750","article-title":"Mondo: unifying diseases for the world, by the world","author":"Vasilevsky","year":"2022"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e78518","DOI":"10.1371\/JOURNAL.PONE.0078518","article-title":"Drug repositioning by kernel-based integration of molecular structure, molecular activity, and phenotype data","volume":"8","author":"Wang","year":"2013","journal-title":"PloS one"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1039\/C2MB05450G","article-title":"Predicting drug targets based on protein domains","volume":"8","author":"Wang","year":"2012","journal-title":"Mol. Biosyst."},{"key":"B69","doi-asserted-by":"publisher","first-page":"D1074-D1082","DOI":"10.1093\/NAR\/GKX1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic acids Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/JAMA.2020.1166","article-title":"Estimated research and development investment needed to bring a new medicine to market, 2009-2018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"key":"B71","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/J.JBI.2015.03.009","article-title":"Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles","volume":"55","author":"Xu","year":"2015","journal-title":"J. Biomed. Inf."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1021\/CI500340N","article-title":"Drug-disease association and drug-repositioning predictions in complex diseases using causal inference-probabilistic matrix factorization","volume":"54","author":"Yang","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e28025","DOI":"10.1371\/JOURNAL.PONE.0028025","article-title":"Systematic drug repositioning based on clinical side-effects","volume":"6","author":"Yang","year":"2011","journal-title":"PloS one"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e87864","DOI":"10.1371\/JOURNAL.PONE.0087864","article-title":"Construction of drug network based on side effects and its application for drug repositioning","volume":"9","author":"Ye","year":"2014","journal-title":"PloS one"},{"key":"B75","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1093\/BIOINFORMATICS\/BTZ418","article-title":"deepDR: a network-based deep learning approach to in silico drug repositioning","volume":"35","author":"Zeng","year":"2019","journal-title":"Bioinforma. Oxf. Engl."},{"key":"B76","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/J.YMETH.2018.06.001","article-title":"Predicting drug-disease associations and their therapeutic function based on the drug-disease association bipartite network","volume":"145","author":"Zhang","year":"2018","journal-title":"Methods (San Diego, Calif.)"},{"key":"B77","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/ijms17020246","article-title":"Systems pharmacology in small molecular drug discovery","volume":"17","author":"Zhou","year":"2016","journal-title":"Int. J. Mol. Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1470931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T07:11:39Z","timestamp":1737529899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1470931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":77,"alternative-id":["10.3389\/fphar.2024.1470931"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1470931","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"article-number":"1470931"}}